Table 1. Baseline characteristics of the patients treated with BOC or TVR.
| Parameter | BOC (n = 46) | TVR (n = 113) |
|---|---|---|
| Age (years)* | 45.4 (41.6–50.9) | 48.3 (43–51.4) |
| Male gender, no. (%) | 35 (76.1) | 92 (81.4) |
| IL28B rs12979860 CT/TT, no. (%) ± | 25 (59.5) | 70 (70) |
| HCV subtype 1a, no. (%) # | 27 (66) | 62 (66.7) |
| Plasma HCV RNA >8*105 IU/mL, no. (%) | 37 (80·4) | 77 (68.1) |
| Cirrhosis, no. (%) ¶ | 21 (51.2) | 42 (45.7) |
| Liver stiffness | 14.8 (6.8–21) | 12,3 (7.9–19.5) |
| Platelets (cells/μL) | 178 (119–228) | 168 (107–220) |
| Albumin (g/dL) | 4 (3.9–4.3) | 4 (3.9–4.2) |
| Low-density lipoprotein cholesterol (mg/dL)* | 103 (77.7–120) | 71 (46–102) |
| Alanine aminotransferase, IU/mL* | 62 (39–96) | 63 (41–97) |
| Previous response to anti-HCV therapy § | ||
| Naive, no. (%) | 19 (41.3) | 26 (23) |
| Null responders, no. (%) | 6 (13) | 36 (31.9) |
| Partial responders, no. (%) | 0 | 11 (9.7) |
| Relapsers, no. (%) | 14 (30.4) | 19 (16.8) |
| Other, no. (%) | 7 (15.2) | 21 (18.6) |
| CD4 cell count (cells/μL)* | 536 (370–670) | 630 (414–802) |
| Undetectable HIV RNA, no. (%) | 37 (80.4) | 96 (85) |
*Median (interquartile range);
±available in 100 patients receiving TVR and 42 subjects receiving BOC;
#available in 93 patients receiving TVR and 41 subjects receiving BOC;
¶available in 92 patients receiving TVR and 41 subjects receiving BOC;
§as referred to dual therapy with peg-IFN plus RBV.